These studies highlight the value of investigating pharmacokinetic behavior and measuring total HER3 or pHER3/HER3 ratio in tumor, and the value of skin biopsies as potential surrogate markers for efficacy and guiding optimal dosing in the clinic. The gene discussed is ERBB3; the disease is neoplasm.